Rheumatic heart disease and congenital heart disease
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age older than 18 years and younger than 70 years; 2. Preoperative coagulation function and platelet numbers were normal; 3. Signed informed consent; 4. Warfarin dose can be tracked and administered for at least 3 months; 5. Warfarin reached a stable dose (INR was maintained between 1.8 and 2.5 after 6 consecutive monitoring ).
Exclusion criteria
Exclusion criteria: 1. liver or kidney dysfunction, or chronic liver and kidney diseases associated with chronic renal insufficiency, chronic hepatitis or cirrhosis; 2. hematological diseases; 3. patients who cannot take warfarin as instructed or cannot follow up; 4. incomplete clinical data collection or defective DNA sequencing of tissue specimens. 5. bleeding or death; 6. atrial or valvular thrombosis detected by echocardiography during follow-up; 7. drug combination of antiplatelet or non-steroidal anti-inflammatory drugs; 8. vegans.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| height;Daily Stable Dose;Age;Weight;Body surface area;sex;Previous thromboembolism;Somke;Hypertension;Diabetes mellitus;ACEI;ß-blocker;Amiodarone;rs9923231;rs9934438;rs7196161;rs7294;rs1057910;rs2069514;rs887829;rs699664; | — |
Countries
China
Contacts
Public ContactTang yanhua
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed